ST6GAL1 (F6C3D) Rabbit Monoclonal Antibody #74141

Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1, SIAT1) catalyzes the addition of alpha2,6-linked sialic acids onto terminal N-glycans of cell-surface and secreted glycoproteins (1,2). The sialyltransferase is predominantly located within the trans-Golgi network but also exists as a soluble form within the extracellular matrix. It is widely expressed across multiple tissues, with high levels in the liver, ovary, kidney, and lung (3). ST6GAL1 is a critical regulator of cellular survival and development; it protects macrophages from TNFR1-induced apoptosis (4), modulates monocyte-macrophage differentiation (5), preserves stem cell pluripotency (6), and is a necessary mediator for somatic cell reprogramming (7). ST6GAL1 upregulation is a pathological hallmark of several malignancies, most notably pancreatic, prostate, breast, and ovarian cancers (8). The aberrant elevation of alpha-2,6-sialylation driven by ST6GAL1 promotes a highly aggressive phenotype by facilitating cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, invasion, metastasis, and therapy resistance (9).